hyperimmune bovine colostrum
Animal productexperimental
Clinical trial activity
6 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
1
Earliest trial started Jul 1, 2008 (NCT00699569)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Unspecified targetImmunity, passive
immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSEP5SDKM7A0 ↗
Also known as
- hyper-immune bovine colostrum
- hyperimmune bovine colostrum
- hyperimmune colostrum
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03281655 | Phase 2 | Mar 31, 2020 | University of Athens, University of Messina, University of Victoria |
| NCT02649075 | N/A | Feb 29, 2016 | Entera Health, Inc |
| NCT01968382 | Phase 2 | Dec 1, 2014 | Immuron Ltd., National Institute on Alcohol Abuse and Alcoholism (NIAAA), Virginia Commonwealth University |
| NCT01466894 | Phase 2 | Dec 1, 2012 | Immuron Ltd. |
| NCT00772590 | Phase 4 | Mar 1, 2009 | University of New South Wales |
| NCT00699569 | N/A | Jul 1, 2008 | Tel Aviv University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immuron Ltd. | For profit | 2 | 1 | 1 | 2012 |
| Entera Health, Inc | For profit | 1 | 1 | 1 | 2016 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 0 | 1 | 2014 |
| Tel Aviv University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| University of Athens | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Messina | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of New South Wales | Academic/Hospital | 1 | 1 | 1 | 2009 |
| University of Victoria | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 1 | 1 | 2014 |
9 organizations
Page 1 / 1